YD Bio Ltd
NASDAQ:YDES
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (1 203.3), the stock would be worth $12.19 (123% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 538.9 | $5.46 |
0%
|
| 3-Year Average | 1 203.3 | $12.19 |
+123%
|
| 5-Year Average | 1 203.3 | $12.19 |
+123%
|
| Industry Average | 4.7 | $0.05 |
-99%
|
| Country Average | 2.1 | $0.02 |
-100%
|
Forward EV/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| TW |
|
YD Bio Ltd
NASDAQ:YDES
|
385m USD | 538.9 | -58 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
308.8B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 351.6 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
102.4B ZAR | 8.9 | 10.6 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
68.5B USD | 0 | 38 690 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
55.3B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
37.6B CHF | 0 | 0 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.8B USD | 14.2 | -3 284.6 | |
| US |
|
Coupang Inc
F:788
|
31.5B EUR | 0.9 | 174.3 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
30.1B ZAR | 9.9 | 6.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.3 |
| Median | 2.1 |
| 70th Percentile | 3.6 |
| Max | 385 201.6 |
Other Multiples
YD Bio Ltd
Glance View
YD Bio Ltd. engages in the development of detection and therapeutic technologies. The company is headquartered in Taipei City, Taipei. The company went IPO on 2025-08-29. The firm is focused on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of diseases with unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. The company is focused on advancing a diversified portfolio of healthcare solutions across oncology diagnostics, regenerative medicine and clinical trial support. The company is a supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. Its core programs include Blood-Based Cancer Detection, Stem Cell- and Exosome-Based Ophthalmology Therapies, and Clinical Trial and AncillaryServices. The company is developing proprietary DNA methylation-based detection technology for a range of cancers, which includes a screening test for the early detection of pancreatic cancer and a monitoring test for recurrent breast cancer.
